http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Naiyer, Afzal J.,Shah, Jayesh,Hernandez, Lincoln,Kim, Soo-Youl,Ciaccio, Edward J.,Cheng, Jianfeng,Manavalan, Sanil,Bhagat, Govind,Green, Peter H.R. Mary Ann Liebert 2008 Thyroid Vol.18 No.11
<P>BACKGROUND: Individuals with active celiac disease (CD+) have an increased incidence of thyroid dysfunction, which improves on a gluten-free diet (CD-). We investigated whether tissue transglutaminase-2 IgA antibodies (anti-TGase II) present in sera of patients with celiac disease react with thyroid tissue and possibly contribute to thyroid disease. METHODS: Serum from 40 active celiac patients taken before a gluten-free diet (CD+), 46 patients on a gluten-free diet (CD-), 40 normal controls (NC), and 25 with Crohn's disease (CROHN) was used. All sera were screened for antithyroperoxidase antibodies (TPO-AB) and thyroglobulin antibodies (TG-AB), and indirect immunofluorescence (IIF) was performed on primate thyroid tissue sections using TPO-AB- and TG-AB-negative sera. RESULTS: IIF with thyroid seronegative, anti-TGase II-positive CD+ sera (n = 23) demonstrated staining of thyroid follicular cells and extracellular matrix, in an identical pattern with monoclonal anti-human TGase II antibody. Evidence of TGase II as the antigen in thyroid tissue was supported by elimination of the IIF pattern when sera were depleted of anti-TGase II by pretreatment with human recombinant TGase II. No staining of thyroid tissue was observed when sera from CD+ patients that were negative for TGase II antibodies, or sera from NC subjects were used. Thyroid antibodies were found in 43% of CD+ patients, significantly higher than NC and CROHN patients (p < 0.0001). In addition, a positive correlation was observed between anti-TGase II and TPO-AB titers (p = 0.0001; r = 0.63). CONCLUSIONS: Anti-TGase II antibodies bind to TGase II in thyroid tissue, and titers correlate with TPO antibody titers. These findings suggest that anti-TGase II antibodies could contribute to the development of thyroid disease in celiac disease.</P>
Yousaf, Nageen,Afzal, Sibtain,Hayat, Tehreem,Shah, Jasmin,Ahmad, Nafees,Abbasi, Rashda,Ramzan, Khushnooda,Jan, Rasul,Khan, Imran,Ahmed, Jawad,Siraj, Sami Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.22
Background: Vitamin D receptor (VDR) gene has been a subject of extensive pharmacogenetic research recently. Association studies between different types of cancers including prostate cancer (PCa) and VDR gene polymorphism have also been conducted. The objective of this study was to find possible associations between PCa and VDR gene polymorphisms in the Pakistani population. Materials and Methods: A total of 162 subjects, including prostate cancer patients and controls, were genotyped for Apa I, Taq I and Fok I polymorphisms in the VDR gene using allele specific PCR, PCR-RFLP and direct DNA sequencing. Allelic frequencies were tested for Hardy-Weinberg equilibrium and associations between the genetic markers and PCa were calculated using logistic regression. Results: Apa I CC genotype was found to have strongest association with PCa risk, and "A" genotype was found to have protective effect. Fok I and Taq I did not have appreciable levels of association with PCa, although Taq I "TC" heterozygotes seemed to have some protective effect. Similarly the "C" allele of Fok I also seemed to have protective effect. Conclusions: To our knowledge, this is the first report showing association between VDR gene polymorphisms and PCa in Pakistan. Our findings may be somewhat skewed because of small sample size and tendency of consanguineous marriages in Pakistani society; nevertheless, it shows the trend of association and protective effects of certain VDR gene polymorphisms against PCa.
Iqra Mir,Sania Aamir,Syed Rizwan Hussain Shah,Muhammad Shahid,Iram Amin,Samia Afzal,Amjad Nawaz,Muhammad Umer Khan,Muhammad Idrees 질병관리본부 2022 Osong Public Health and Research Persptectives Vol.13 No.2
The coronavirus disease 2019 (COVID-19) pandemic rapidly spread globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is a positive-sense single-stranded RNA virus with a reported fatality rate ranging from 1% to 7%, and people with immune-compromised conditions, children, and older adults are particularly vulnerable. Respiratory failure and cytokine storm-induced multiple organ failure are the major causes of death. This article highlights the innate and adaptive immune mechanisms of host cells activated in response to SARS-CoV-2 infection and possible therapeutic approaches against COVID-19. Some potential drugs proven to be effective for other viral diseases are under clinical trials now for use against COVID-19. Examples include inhibitors of RNA-dependent RNA polymerase (remdesivir, favipiravir, ribavirin), viral protein synthesis (ivermectin, lopinavir/ritonavir), and fusion of the viral membrane with host cells (chloroquine, hydroxychloroquine, nitazoxanide, and umifenovir). This article also presents the intellectual groundwork for the ongoing development of vaccines in preclinical and clinical trials, explaining potential candidates (live attenuated-whole virus vaccines, inactivated vaccines, subunit vaccines, DNA-based vaccines, protein-based vaccines, nanoparticle-based vaccines, virus-like particles and mRNA-based vaccines). Designing and developing an effective vaccine (both prophylactic and therapeutic) would be a long-term solution and the most effective way to eliminate the COVID-19 pandemic.
Abdul Haleem,Sidra Bibi Syaal,Muhammad Ajmal,Jaweria Ambreen,Sajid Rauf,Nasir Ali,Saz Muhammad,Afzal Shah,Muhammad Abid Zia,Muhammad Siddiq 한국화학공학회 2020 Korean Journal of Chemical Engineering Vol.37 No.4
Here in, we demonstrate facile fabrication of silver and palladium nanoparticles in dual responsive poly(Nisopropylacrylamide- co-2-Acrylamido-2-methylpropane sulfonic acid) microgel with temperature- and pH-dependent catalytic potential. Palladium-based catalyst showed better catalytic efficiency as compared to silver-based catalyst for degradation of Rhodamine-B and P-Nitrophenol in aqueous medium under the same set of reaction conditions. The responsive nature of the microgel was found to be useful to tune the catalytic activity of the as-prepared catalysts, and reduction rate was enhanced with the pH and temperature elevation of the reaction medium; however, the increasing trend was slowed in the volume phase transition region of the microgel. Under a specific set of reaction conditions, the reduction of Rhodamine-B was as fast as 0.968 and 0.571 min1 when catalyzed with palladium and silver based catalysts, respectively. The hydrodynamic radius of the particles of microgel support was found to be in the range of 65- 180 nm when pH and temperature of the medium were varied in the range of 2-12 and 25-45, respectively. The estimated diameter of silver and palladium nanoparticles fabricated in the microgel support under the same set of reaction conditions was 9-15 and 7-11 nm, respectively.